TTP Diagnostic Criteria and Clinical Scoring Tools

The defining diagnostic criterion for thrombotic thrombocytopenic purpura is an ADAMTS13 activity level below 10 percent, measured in the context of thrombocytopenia and microangiopathic hemolytic anemia. ADAMTS13 is a blood enzyme responsible for trimming an oversized clotting protein called von Willebrand factor; when the enzyme is severely deficient, tiny clots form throughout the body’s small blood vessels, consuming platelets and shredding red blood cells in the process. Beyond that single laboratory threshold, an entire framework of clinical scoring systems, classification schemes, and treatment-response definitions helps doctors decide how urgently to act, what kind of TTP they are dealing with, and how to manage the disease over months and years.

The Central Laboratory Threshold

For decades, TTP was diagnosed mainly on clinical grounds: a patient showed up with a dangerously low platelet count, signs that red blood cells were being destroyed in circulation, and sometimes neurological symptoms, fever, or kidney trouble. That classic “pentad” of findings was useful but imprecise, because several other conditions can look almost identical at the bedside. The field shifted when researchers established that ADAMTS13 activity below 10 percent reliably distinguishes TTP from those mimics.¹ That cutoff is now accepted internationally as the diagnostic standard.²

In practice, confirming the diagnosis means drawing blood for an ADAMTS13 activity assay, ideally before starting plasma exchange. The problem is that results can take a day or more to come back from a reference lab, and TTP is a medical emergency: untreated, it can kill quickly. So clinicians face a practical gap between the moment they suspect TTP and the moment the lab confirms or excludes it. That gap is where clinical scoring tools come in.

Immune-Mediated Versus Congenital TTP

Once severe ADAMTS13 deficiency is confirmed, the next step is figuring out why the enzyme is missing. The answer splits TTP into two categories with different treatment paths. The far more common form is immune-mediated TTP, where the patient’s immune system produces autoantibodies that attack and neutralize ADAMTS13.³ Detecting those antibodies in the blood confirms the immune mechanism and signals that immunosuppressive treatment will be necessary to shut down the autoimmune attack.

The rarer form, congenital TTP, results from inherited mutations in the ADAMTS13 gene itself. These patients are born with little or no functional enzyme and may experience their first episode in infancy, childhood, or sometimes not until adulthood, particularly during pregnancy or other physiological stress.⁴ Genetic testing confirms congenital TTP. In both forms, ADAMTS13 activity is severely deficient, but the cause and the long-term management strategy differ substantially. Immune-mediated TTP requires immunosuppression; congenital TTP is managed primarily with regular plasma infusions to replace the missing enzyme.

Clinical Scoring Tools for Early Decisions

Because waiting for ADAMTS13 results while a patient deteriorates is not an option, two scoring systems help clinicians estimate the probability of severe ADAMTS13 deficiency and justify starting plasma exchange before lab confirmation arrives.

The PLASMIC score uses seven clinical and laboratory variables that are readily available in most emergency departments: platelet count, signs of hemolysis, absence of active cancer, absence of organ transplant history, mean corpuscular volume (a red blood cell size measure), kidney function, and an international normalized ratio for clotting. A score of 6 or 7 out of 7 puts a patient in the high-risk category. In external validation, a high PLASMIC score predicted severe ADAMTS13 deficiency with about 90 percent sensitivity and 92 percent specificity, with a negative predictive value of 98 percent, meaning a low score effectively rules TTP out.⁵

The French TMA Reference Center score takes a different approach with just three variables: creatinine level, platelet count, and the presence of antinuclear antibodies. When all three criteria are met (creatinine no higher than roughly 200 µmol/L, platelets no higher than 30 × 10⁹/L, and a positive antinuclear antibody test), the specificity reaches about 98 percent, virtually eliminating false positives. When at least one criterion is met, sensitivity climbs to about 99 percent, catching nearly every case of severe ADAMTS13 deficiency.⁶ Both scoring tools have also been used to estimate short-term mortality risk: first episodes of acquired TTP tend to score higher on both models compared with relapses, reflecting a greater initial severity.⁷

Where the Scoring Tools Struggle

Both scores were developed and validated primarily in younger adult populations, and their performance can erode in groups whose baseline lab values differ from that population. In patients aged 60 and older, the sensitivity of the French score dropped to about 77 percent, compared with 100 percent in adults under 40.⁸ Older patients are more likely to have coexisting kidney disease, cancer, or other conditions that muddy the variables these tools rely on. The same concern applies in pregnancy, critical illness, and the setting of active malignancy, where overlapping lab abnormalities reduce the tools’ ability to separate TTP from other diagnoses.⁹

The takeaway is that clinical scoring tools are excellent for fast triage in straightforward cases, especially for their ability to rule TTP out when the score is low. But in complex patients, they are not reliable enough to serve as standalone diagnostic instruments. ADAMTS13 activity testing remains indispensable, and clinicians in ambiguous situations may need to start empiric plasma exchange while awaiting those results.

Separating TTP from Its Look-Alikes

TTP belongs to a broader family of conditions called thrombotic microangiopathies, all of which cause small-vessel clotting, low platelets, and fragmented red blood cells. The differential diagnosis matters enormously because treatments differ. The most important mimics include atypical hemolytic uremic syndrome, typical hemolytic uremic syndrome, disseminated intravascular coagulation, and, in pregnant patients, HELLP syndrome.

Atypical hemolytic uremic syndrome is caused by dysregulation of the complement system rather than by ADAMTS13 deficiency. Because its clinical presentation can look almost identical to TTP, the ADAMTS13 activity level is what separates them: below 10 percent points toward TTP, while a normal or mildly reduced level in the right clinical context points toward atypical HUS.¹⁰ Typical HUS, more common in children, is linked to infection with Shiga-toxin-producing bacteria and is identified through stool cultures or toxin assays rather than ADAMTS13 testing.¹¹

Disseminated intravascular coagulation can also destroy platelets and red blood cells in small vessels, but it typically presents with dramatically abnormal clotting tests (prolonged prothrombin time, low fibrinogen) that are less prominent in TTP. The ADAMTS13 level again helps: markedly decreased activity favors TTP, while DIC will not show the same severe deficiency.¹²

In pregnancy, a specific challenge arises because HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets) can closely mimic TTP. One study found that an LDH-to-AST ratio above roughly 22 favors TTP over HELLP in a third-trimester patient presenting with overlapping features, and the authors recommend obtaining a hematology consult and considering plasma exchange when this ratio is elevated.¹³ Pregnancy-associated TTP also intersects with the scoring-tool limitations mentioned earlier, since pregnancy itself alters many of the lab values those tools depend on.

Defining Treatment Response, Remission, and Relapse

Standardized definitions of treatment outcomes are just as important as diagnostic criteria, because clinical trials, registries, and treatment guidelines all need to speak the same language. An international working group established consensus terminology for TTP outcomes, covering clinical response, remission, and relapse for both immune-mediated and congenital forms.¹⁴

In broad terms, clinical response means platelet counts are rising and hemolysis markers are improving during active treatment. Remission means the patient has achieved a sustained platelet recovery and is off plasma exchange. Relapse refers to disease recurrence after a defined period of remission. A more specific distinction separates “exacerbation” from “relapse”: exacerbation describes a return of disease during treatment or within 30 days of stopping plasma exchange, while relapse applies when disease recurs 30 or more days after treatment has stopped.

Refractory TTP is defined as failure to achieve clinical response after five sessions of plasma exchange, or an initial improvement followed by worsening while still receiving treatment. Patients meeting these criteria have historically had very poor outcomes, though newer agents are reducing the incidence of truly refractory disease.¹⁵

Caplacizumab and Criteria for Targeted Therapy

The arrival of caplacizumab, a drug that directly blocks the interaction between von Willebrand factor and platelets, changed the treatment landscape for immune-mediated TTP. International guidelines from the International Society on Thrombosis and Haemostasis conditionally recommend caplacizumab for patients experiencing an acute immune-mediated TTP event, whether it is a first episode or a relapse.¹⁶

The evidence from two randomized trials showed that patients receiving caplacizumab had fewer exacerbations during and shortly after plasma exchange. However, those same patients experienced more relapses after the drug was stopped, likely because caplacizumab controls the downstream clotting problem without addressing the underlying autoimmune attack on ADAMTS13. That nuance matters for how clinicians define success: a patient may respond quickly to caplacizumab but still need aggressive immunosuppression to prevent relapse once the drug is discontinued. The guideline panel also flagged that patients on caplacizumab had more bleeding side effects, which means clinicians weigh the criteria for starting the drug against the patient’s individual bleeding risk.¹⁷

Monitoring Criteria During Remission

Surviving an acute episode of immune-mediated TTP is not the end of the story. The disease has a well-documented tendency to relapse, sometimes years later. What predicts relapse most reliably is a return of severe ADAMTS13 deficiency during remission: if the enzyme level drops back below 10 percent while the patient feels fine and has normal blood counts, the risk of a clinical flare rises substantially.

This observation has given rise to a monitoring strategy in which patients have their ADAMTS13 activity checked roughly every three months after remission.¹⁸ When the level falls below 10 percent in a patient who is otherwise clinically well, that biochemical relapse triggers consideration of preemptive rituximab, an antibody therapy that depletes the B cells responsible for producing anti-ADAMTS13 autoantibodies. In a cross-sectional analysis following patients over 12 years, preemptive rituximab dropped the relapse rate from roughly half an episode per year to zero in the treated group, and relapse-free survival was longer compared with untreated patients who had similar ADAMTS13 deficiency during remission.¹⁹ A later study confirmed that preemptive rituximab prevents long-term relapses, and researchers began investigating whether the physical shape of the ADAMTS13 molecule at peak recovery can predict how soon a patient will need retreatment.²⁰

The practical criterion, then, is straightforward even if the biology is complex: ADAMTS13 activity below 10 percent during clinical remission warrants preemptive treatment. This quarterly monitoring approach has shifted the management of TTP from a purely reactive model, treating crises as they arise, to a semi-preventive one.

Long-Term Health After TTP

As survival from acute episodes has improved, doctors are increasingly recognizing that TTP leaves a trail of chronic health problems. Patients who survive one or more episodes face elevated risks of obesity, cardiovascular disease, chronic kidney disease, neuropsychiatric impairment, and reduced overall life expectancy.²¹ Cognitive difficulties and mood disorders are common complaints, likely tied to the small-vessel clotting events that affect the brain during acute episodes.

For women, pregnancy after TTP carries particular risks. The physiological changes of pregnancy can trigger relapse in both immune-mediated and congenital forms. Pre-pregnancy counseling and close ADAMTS13 monitoring throughout gestation are part of the standard follow-up plan for TTP survivors. Obstetric complications in this group are more frequent, adding another layer to post-TTP care.

These long-term sequelae have prompted calls for structured survivorship programs, similar to what exists for cancer survivors. Right now, follow-up practices vary widely between institutions. Some centers run dedicated TTP clinics with quarterly ADAMTS13 checks and multidisciplinary support; others discharge patients back to general hematology or primary care after the acute episode resolves, where long-term monitoring may be inconsistent.

Pediatric TTP and Diagnostic Nuances

TTP in children is uncommon but does occur, and the diagnostic criteria are the same: ADAMTS13 activity below 10 percent with appropriate clinical findings. However, the balance between congenital and immune-mediated forms tilts differently in pediatric patients. Congenital TTP makes up a larger share of childhood cases than it does in adults, because the inherited form often declares itself early in life. Some children present in the neonatal period with severe jaundice and low platelets; others coast through childhood and are diagnosed only after an unexplained episode of hemolytic anemia or thrombocytopenia during an infection or other physiological stress.²²

In pediatric immune-mediated TTP, the challenge is that some of the scoring tools used in adults rely on lab thresholds calibrated for adult reference ranges. Creatinine values, for example, vary with age and body size in children, which can make the French score’s cutoff less applicable. Diagnosis in children therefore leans even more heavily on ADAMTS13 testing, with clinical suspicion triggered by unexplained thrombocytopenia and hemolysis that doesn’t fit more common pediatric diagnoses like immune thrombocytopenia or hemolytic uremic syndrome from bacterial infection. Full evaluation of ADAMTS13 activity, antibodies, antigen levels, and, when congenital TTP is suspected, genetic analysis of the ADAMTS13 gene, forms the diagnostic workup in this age group.